Although it is known that the methylation of DNA in 59 promoters suppresses gene expression, the role of DNA methylation in gene bodies is unclear 1-5 . In mammals, tissue-and cell type-specific methylation is present in a small percentage of 59 CpG island (CGI) promoters, whereas a far greater proportion occurs across gene bodies, coinciding with highly conserved sequences 5-10 . Tissuespecific intragenic methylation might reduce 3 , or, paradoxically, enhance transcription elongation efficiency 1,2,4,5 . Capped analysis of gene expression (CAGE) experiments also indicate that transcription commonly initiates within and between genes 11-15 . To investigate the role of intragenic methylation, we generated a map of DNA methylation from the human brain encompassing 24.7 million of the 28 million CpG sites. From the dense, high-resolution coverage of CpG islands, the majority of methylated CpG islands were shown to be in intragenic and intergenic regions, whereas less than 3% of CpG islands in 59 promoters were methylated. The CpG islands in all three locations overlapped with RNA markers of transcription initiation, and unmethylated CpG islands also overlapped significantly with trimethylation of H3K4, a histone modification enriched at promoters 16 . The general and CpGisland-specific patterns of methylation are conserved in mouse tissues. An in-depth investigation of the human SHANK3 locus 17, 18 and its mouse homologue demonstrated that this tissue-specific DNA methylation regulates intragenic promoter activity in vitro and in vivo. These methylation-regulated, alternative transcripts are expressed in a tissue-and cell type-specific manner, and are expressed differentially within a single cell type from distinct brain regions. These results support a major role for intragenic methylation in regulating cell context-specific alternative promoters in gene bodies.
Although it is known that the methylation of DNA in 59 promoters suppresses gene expression, the role of DNA methylation in gene bodies is unclear [1] [2] [3] [4] [5] . In mammals, tissue-and cell type-specific methylation is present in a small percentage of 59 CpG island (CGI) promoters, whereas a far greater proportion occurs across gene bodies, coinciding with highly conserved sequences [5] [6] [7] [8] [9] [10] . Tissuespecific intragenic methylation might reduce 3 , or, paradoxically, enhance transcription elongation efficiency 1, 2, 4, 5 . Capped analysis of gene expression (CAGE) experiments also indicate that transcription commonly initiates within and between genes [11] [12] [13] [14] [15] . To investigate the role of intragenic methylation, we generated a map of DNA methylation from the human brain encompassing 24.7 million of the 28 million CpG sites. From the dense, high-resolution coverage of CpG islands, the majority of methylated CpG islands were shown to be in intragenic and intergenic regions, whereas less than 3% of CpG islands in 59 promoters were methylated. The CpG islands in all three locations overlapped with RNA markers of transcription initiation, and unmethylated CpG islands also overlapped significantly with trimethylation of H3K4, a histone modification enriched at promoters 16 . The general and CpGisland-specific patterns of methylation are conserved in mouse tissues. An in-depth investigation of the human SHANK3 locus 17, 18 and its mouse homologue demonstrated that this tissue-specific DNA methylation regulates intragenic promoter activity in vitro and in vivo. These methylation-regulated, alternative transcripts are expressed in a tissue-and cell type-specific manner, and are expressed differentially within a single cell type from distinct brain regions. These results support a major role for intragenic methylation in regulating cell context-specific alternative promoters in gene bodies.
To determine if intragenic DNA methylation is functional, we first generated high-resolution methylome maps of the human brain frontal cortex grey matter from two individuals. We developed two complementary next-generation sequencing-based approaches to detect methylated and unmethylated DNA. The first, methylated DNA immunoprecipitation and sequencing (MeDIP-seq), uses antibodybased immunoprecipitation of 5-methylcytosine and sequencing to map the methylated fraction of the genome. In the second method, unmethylated CpG sites are identified at single CpG site resolution by sequencing size-selected fragments from parallel DNA digestions with the methyl-sensitive restriction enzymes (MREs) HpaII, Hin6I and AciI (MRE-seq, Supplementary Fig. 1 ).
Of the 28 million CpGs in the haploid human genome, MeDIP-seq covered approximately 24 million at 100-300 base pair resolution, whereas MRE-seq detected approximately 1.7 million unmethylated sites at single CpG site resolution ( Supplementary Figs 2 and 3 ). The two methods detect different fractions of the genome, with more frequent MeDIP-seq reads observed in the commonly methylated CpG-poor fraction ( Supplementary Fig. 4 ). Similar results were obtained with frontal cortex from a second individual (Supplementary Figs 5 and 6; Supplementary Excel File 1).
We determined the DNA methylation status of approximately 27,100 of the 27,639 CGIs in the human genome from the combined MRE-seq and MeDIP-seq data sets ( Supplementary Figs 7 and 8 ). MRE-seq scores and MeDIP-seq scores (see Supplementary Methods) for CGIs are anticorrelated ( Fig. 1a , Pearson correlation 5 20.44, P , 10 216 ). An exception is the differentially methylated regions (DMRs) of imprinted genes that have significant MRE-seq and MeDIP-seq signals ( Supplementary  Fig. 9 ). In contrast to array-based methods, MRE-seq and especially MeDIP-seq can interrogate the methylation status of a large fraction of repetitive sequences, which comprise more than 40% of the genome (Supplementary Excel File 2). Genome-wide, about 75% of repetitive regions are covered by MeDIP reads, compared to 3% for MRE-seq, consistent with high methylation of repeat sequences. Validation of MRE-seq and MeDIP-seq by standard bisulphite cloning and sequencing of 24 CGI loci ( Fig. 1b ; Supplementary Fig. 10a -m and Supplementary Excel File 3) supports the accuracy of MeDIP-seq and MRE-seq for determining methylation status. Across gene bodies, including CGIs and non-CGI regions, we found that the average methylation level is decreased at the 59 ends of genes, including ,300 bp downstream of the transcription start site (TSS), where methylation might inhibit efficient inititation 19 , but increases in gene bodies as reported previously 1, 4, 20, 21 ( Supplementary Fig. 11 ). However, gene bodies are often large and may contain multiple discrete regulatory sequences. This type of analysis might obscure a more specific role for DNA methylation in regulating particular regulatory sequences within gene bodies.
Because CGIs frequently overlap regulatory DNA sequences, our investigation focused on the DNA methylation status of intragenic CGIs relative to CGIs from canonical 59 promoter regions, intergenic and 39 regions. Overall, 16% of all CGIs in the human brain were methylated, whereas 98% of CGIs associated with annotated 59 promoters were unmethylated ( Fig. 1c ; Supplementary Fig. 12 ). Notably, 34% of all intragenic CGIs were methylated ( Fig. 1c ). Thus, DNA methylation may serve a broader role in intragenic compared to 59 promoter CGIs in the human brain.
We next addressed whether the general pattern of frequent intragenic CGI methylation and rare 59 promoter CGI methylation is evolutionarily conserved. Comparison of our DNA methylation profile of the human brain with reduced representation bisulphite sequencing-based methylation data from the mouse brain and eight additional tissues 16 showed the same general pattern ( Fig. 1c ). In addition, tissue-specific methylation, defined here as methylation in at least one but not all tissues, is far more common at intragenic CGIs than 59 promoters (24.4% versus 2%). The methylation status of intragenic CGIs in the human and mouse brains was concordant for 80% of the orthologous CGIs (Supplementary Table 1 ). Greater than 99% of orthologous 59 CGIs were unmethylated in human and mouse brain tissue (Supplementary Table 1 ). The relative lack of methylation in 59 promoter CGIs indicates that DNA methylation at these sites has only a limited role in regulating tissuespecific transcription initiating from the canonical 59 promoter region. In contrast, the tissue-specific and highly conserved specific pattern of intragenic CGI methylation indicates that it serves a functional role for a significant proportion of genes. The pattern of methylation in intragenic CGIs cannot be accounted for by presence of transposable elements in the CGIs, as just 1.5% of the sequences within these CGIs are annotated as repetitive (Supplementary Excel File 2). Because many genes have alternative promoters, classically located upstream of the translation start site but also commonly present within genes 15 , we reasoned that a major function of the frequent, tissue-specific and conserved intragenic methylation may be to regulate the activity of such alternative promoters, as shown in two genes recently 5, 22 . To address this hypothesis genome-wide, we determined whether the CGI loci overlap with sites of transcription initiation and/or with histone methylation marks typically found in association with 59 promoters.
First, we assessed the relationship between the methylation status of CGIs in the human brain with CAGE tag data sets from several human tissues 12, 23 . CAGE tags are derived from mRNA sequenced in the proximity of the 59-cap site and those tags that map onto unique genomic regions correspond to potential transcriptional start sites [11] [12] [13] [14] [15] 24 , or in a few cases may be derived from post-transcriptionally processed RNAs 25 . The presence of CAGE tags from one or more tissue types suggests the underlying genomic sequence harbours a promoter, the activity of which depends on the cellular context and epigenetic status. Consistent with this notion, nearly all 59 promoter CGIs had CAGE tag clusters mapped to them from one or more tissues ( Fig. 2a ), although 98% of them lack DNA methylation in the human brain. CAGE tags from one or multiple tissues also mapped to intragenic, intergenic and 39 CGIs, a significant proportion of which are methylated in brain tissue. A similar relationship between CAGE tag clusters and CGI methylation status was observed in mouse tissues ( Fig. 2a ). Together, these data indicate that sites of tissue-specific intragenic methylation overlap with potential alternative CGI promoters embedded within genes, and that this relationship is evolutionarily conserved.
To test further the hypothesis that a significant fraction of intragenic CGIs function as alternate promoters, we generated a map of methylation is prevalent in gene bodies and rare in 59 promoter regions. a, Inverse correlation between MeDIP-seq and MRE-seq in 59 promoter, intragenic, 39 and intergenic CGIs. Unmethylated CpGs are shown as an MRE score (a normalized number of reads interrogating each CGI, see Supplementary Methods) on the Y-axis. Methylated regions are shown as reads per kilobase (reads kb 21 ) from MeDIP-seq on the X-axis. b, Top, MAPK4 with methylated regions (MeDIP-seq, dark brown) and unmethylated CpG sites (MRE-seq, green). Zoomed-in views of each CGI are shown below, and percent methylation for each CpG site assessed by bisulphite sequencing is graphed to the right. c, Percentage of CGIs that show methylation in a particular tissue, methylation in one or more tissues (mouse 16 , at least one cell type), or tissuespecific methylation (mouse, differentially).
trimethylation of histone H3 lysine 4 (H3K4me3), an epigenetic mark that coincides with promoters, by ChIP-seq on the human brain. Unmethylated 59 CGI promoters and H3K4me3 overlapped significantly in the human brain ( Fig. 2b ; Supplementary Fig. 13 ), as was also observed in the mouse 16 . Interestingly, for intragenic CGIs the degree of DNA methylation correlated inversely with the level of H3K4me3 signal (Pearson correlation 20.46, P , 10 210 ). The strong overlap of H3K4me3 with unmethylated intragenic CGIs, the inverse correlation between H3K4me3 signal and intragenic CGI DNA methylation, and the presence of CAGE tags from one or more tissues indicate that these intragenic sites function as alternative promoters, 34% of which exhibit tissue-specific methylation. In data from mouse tissues 11, 16 , we found a strong inverse correlation between level of DNA methylation and presence of CAGE tags at intragenic CGIs in liver, lung and brain ( Supplementary Fig. 14) .
Next, we performed genome-wide expression profiling using wholetranscriptome shotgun sequencing (WTSS), also known as RNAseq 26, 30 , on the human frontal cortex sample for which we had generated MeDIP-seq and MRE-seq ChIP-seq data sets. The cDNA library construction protocol used enriches for full-length mRNAs and tags their 59 ends, and in conjunction with computational detection and clipping of these 59 tags, followed by mapping of the adjacent cDNA sequence, allows the inference of putative TSS (Supplementary Methods). Unmethylated, H3K4me3-positive intragenic CGIs were associated with putative TSS significantly more often than methylated, H3K4me3-negative intragenic CGIs. The relationship between DNA methylation, H3K4me3 and transcription initiation sites is illustrated further by a heat map view of all intragenic CGIs based on five independent experiments ( Fig. 2c ; Supplementary Fig. 15 and Supplementary Table 2 ). Thus, our RNA-seq data complement the observations made with CAGE tag data sets, and further strengthen the hypothesis that intragenic methylation regulates alternative promoters.
In parallel with the genome-wide analyses, we investigated indepth a single locus with a 59 promoter CGI, two conserved intragenic CGIs, one conserved 39CGI, and one additional intragenic CGI in humans that is not present in mice. Our prior analysis of this locus, the autism and 22q deletion syndrome gene SHANK3 (refs 17, 18), demonstrated evolutionarily conserved and tissue-specific intragenic methylation at one CGI 7 . The 59 promoter CGI of SHANK3 was unmethylated, whereas one intragenic and one 39 CGI exhibited methylation and two intragenic CGI were predominantly unmethylated ( Fig. 3a ). Bisulphite sequencing across matched tissues from mice and humans revealed strongly conserved patterns of DNA methylation in SHANK3 ( Supplementary Fig. 16 ). The 59 CGI was unmethylated in all tissues analysed in both species, irrespective of SHANK3 expression ( Supplementary Fig. 16 and data not shown).
First, we searched for in vivo evidence of promoters embedded within SHANK3 by integrating sequence conservation (ECRs), evidence of transcription initiation in both mouse and human tissues (CAGE tags), the presence of H3K4me3 in the human brain as well as overlapping H3K4me3 and H3K27me3 peaks from ChIP-seq analyses of embryonic stem (ES) cells 27 . Five intragenic regions were identified with most or all of these features (Fig. 3a ). For two intragenic CGIs, we used 59-RACE to confirm intragenically initiating transcripts in brain, but not lung, originating from ECR22 (transcript 22t) and ECR32 (transcript 32t) in mouse and human tissue ( Fig. 3b and data not shown). Both 22t and 32t are comprised of unique first exons and downstream sequences that correspond to the known exons of the full-length SHANK3, and contain conserved translational start sites in-frame with the full-length SHANK3 protein (Fig. 3b ). ECR22 and ECR32 harbour significant promoter activity, which is abolished by in vitro methylation ( Fig. 3c and Supplementary Fig. 17 ).
In vivo, the DNA methylation status of ECR22 and ECR32 promoters is inversely correlated with 22t and 32t transcription, respectively, and CGIs have features of promoters. a, Methylated CGIs are indicated above the zero line and unmethylated CGIs are below. For the human brain, the methylation data are from the frontal cortex, and CAGE tags are derived from multiple tissues 11, 23 . For the mouse brain, the methylation data are the same as for Fig. 1c , and CAGE data are derived from multiple mouse tissues 11, 12 LETTERS their expression patterns are similar in matching mouse and human tissues ( Supplementary Fig. 18 ). In particular, the tissue-specific DNA methylation levels of ECR32 are also cell-type and brain-region specific ( Supplementary Figs 18 and 19) , and evolutionarily conserved (Fig. 3d ). Treatment of primary cortical astrocytes with a DNA methylation inhibitor increased transcripts from the normally methylated ECR32 intragenic promoter ( Fig. 3e ), but had no effect on the full-length transcript originating from the constitutively unmethylated 59 promoter CGI (Fig. 3f ). Conversely, treatment with a histone deacetylase inhibitor activated the full-length transcript significantly with little change to 32t expression ( Fig. 3f ). Combined inhibition of DNA methylation and histone deacetylase (HDAC) activity did not increase 32t beyond the effect of blocking DNA methylation alone (Fig. 3e ), nor did it increase the full-length transcript expression beyond HDAC inhibition alone (Fig. 3f ). Interestingly, primary astrocytes derived from the hippocampus had opposite methylation and expression levels of ECR32 and 32t relative to cortical astrocytes ( Supplementary Fig. 19 and Fig. 3e ). Additionally, unlike cortical astrocytes, the level of 32t expression in hippocampal astrocytes remained unchanged after HDAC and DNA methylation inhibition (Fig. 3e) . In contrast, an increase in expression of the full-length SHANK3 was observed in both astrocyte populations following treatment with an HDAC inhibitor (Fig. 3f ). Thus, in addition to the brain-region-specific differences between astrocytes, the full-length SHANK3 and 32t seem to be regulated by distinct epigenetic mechanisms within the same cells. Similarly, an intragenic CGI in a second mouse gene, Nfix, also functions as a methylation-regulated intragenic promoter ( Supplementary Fig. 20 ). Increased gene body methylation correlates with increased transcription genome-wide 1,2,4,5 , which is seemingly contradictory to our main conclusion. Indeed, in our human brain data, moderately expressed genes exhibited greater gene body methylation on average ( Supplementary Fig. 21 ). However, these correlations use the average methylation level over the entire gene body rather than examining specific CGI sites with potential regulatory function, and involve gene expression measurements that do not discriminate which transcripts are being measured when multiple overlapping transcripts are present. In contrast, the integration of CAGE tags, H3K4me3 peaks and RNA-seq-inferred TSS allow precise mapping of genomic sites of transcription initiation and promoter function. Despite the stereotype, DNA methylation does not seem to play a major role in gene regulation from 59 CGI promoters of most autosomal genes, where histone acetylation and histone methylation may be more relevant. Our study also highlights an underappreciated complexity of DNA methylation-associated regulation of alternative promoters within gene bodies, including differences in this regulation within a single cell type from distinct brain regions, and in different regions of the same gene in the same cell. In light of the precision afforded by our approach and the new conclusions drawn from it, it may now be possible to reconcile prior controversies on the role of DNA methylation in the regulation of gene expression during development and cancer 28, 29 . The role of intragenic DNA methylation is but one of many possible important new advances afforded by the synthesis of integrative epigenomics and comparative genomics.
METHODS SUMMARY
Genomic DNA was isolated from post mortem brains from 56-and 57-year-old males. Frontal cortex grey matter was macrodissected from a frozen coronal brain section guided by a neuropathologist. DNA, RNA and native chromatin were extracted using standard methods. MRE-seq, MeDIP-seq, H3K4me3 ChIPseq and RNA-seq libraries were sequenced with an Illumina Genome Analyzer II. Computational and statistical analyses were performed with R package and ad hoc programs. 
METHODS
DNA isolation. Cells were lysed in DNA extraction buffer (50 mM Tris pH 8.0, 0.5% sodium dodecyl sulphate, 0.5 mM EDTA pH 8.0, and 1 mg ml 21 proteinase K) overnight at 55 uC. RNA was removed by RNase treatment (40 mg ml 21 , Roche DNase-free RNase) for 1 h at 37 uC. DNA was purified with two phenol/ chloroform/isoamyl alcohol extractions followed by two chloroform extractions using phase-lock gels. DNA was precipitated with sodium acetate and ethanol, washed with 70% ethanol, and resuspended in TE buffer. MRE-seq. Three parallel digests were performed (HpaII, AciI and Hin6I; Fermentas), each with 1-5 mg of DNA. Five units of enzyme per microgram DNA were added and incubated at 37 uC in Fermentas Tango buffer for 3 h. A second dose of enzyme was added (5 units of enzyme per microgram DNA) and the DNA was incubated for an additional 3 h. Digested DNA was precipitated with sodium acetate and ethanol, and 500 ng of each digest were combined into one tube. Combined DNA was size-selected by electrophoresis on a 1% agarose TBE gel. A 100-300 bp gel slice was excised using a sterile scalpel and gel-purified using Qiagen QIAquick columns, eluting in 30 ml of Qiagen EB buffer. Library construction was performed using the Illumina Genomic DNA Sample Kit (Illumina) with single-end adapters, following the manufacturer's instructions with the following changes. For the end repair reaction, T4 DNA polymerase and T4 polynucleotide kinase were excluded and the Klenow DNA polymerase was diluted 1:5 in water and 1 ml used per reaction. For single-end oligo adaptor ligation, adapters were diluted 1:10 in water and 1 ml used per reaction. After the second size selection, DNA was eluted in 36 ml EB buffer using Qiagen QIAquick columns, and 13 ml used as template for PCR, using Illumina reagents and cycling conditions with 18 cycles. After cleanup with Qiagen MinElute columns, each library was examined by spectrophotometry (Nanodrop, Thermo Scientific) and Agilent DNA Bioanalyzer (Agilent). MeDIP-seq. For MeDIP, 5-15 mg DNA isolated as described above was sonicated to ,100-500 bp with a Bioruptor sonicator (Diagenode). Sonicated DNA was end-repaired, A-tailed, and ligated to single-end adapters following the standard Illumina protocol. After agarose size-selection to remove unligated adapters, 2-5 mg of adaptor-ligated DNA was used for each immunoprecipitation using a mouse monoclonal anti-methylcytidine antibody (1 mg ml 21 , Eurogentec). For this, DNA was heat-denatured at 95 uC for 10 min, rapidly cooled on ice, and immunoprecipitated with 1 ml primary antibody per microgram of DNA overnight at 4 uC with rocking agitation in 500 ml immunoprecipitation buffer (10 mM sodium phosphate buffer, pH 7.0, 140 mM NaCl, 0.05% Triton X-100). To recover the immunoabsorbed DNA fragments, 4 ml of rabbit anti-mouse IgG secondary antibody (2.5 mg ml 21 , Jackson Immunoresearch) and 100 ml Protein A/G beads (Pierce Biotechnology) were added and incubated for an additional 2 h at 4 uC with agitation. After immunoprecipitation a total of six immunoprecipitation washes were performed with ice-cold immunoprecipitation buffer. A nonspecific mouse IgG immunoprecipitation (Jackson Immunoresearch) was performed in parallel to methyl DNA immunoprecipitation as a negative control. Washed beads were resuspended in TE buffer with 0.25% SDS and 0.25 mg ml 21 proteinase K for 2 h at 55 uC and then allowed to cool to room temperature. MeDIP and supernatant DNA were purified using Qiagen MinElute columns and eluted in 16 ml EB (Qiagen). Fifteen cycles of PCR were performed on 5 ml of the immunoprecipitated DNA using the single-end Illumina PCR primers. The resulting reactions were purified with Qiagen MinElute columns, after which a final size selection (192-392 bp) was performed by electrophoresis in 2% agarose. Libraries were quality controlled by spectrophotometry and Agilent DNA Bioanalyzer analysis. An aliquot of each library was diluted in EB to 5 ng ml 21 and 1 ml used as template in four independent PCR reactions to confirm enrichment for methylated and de-enrichment for unmethylated sequences, compared to 5 ng of input (sonicated DNA). Two positive controls (SNRPN and MAGEA1 promoters) and two negative controls (a CpG-less sequence on chromosome 15 and GAPDH promoter) were amplified (see Supplementary Materials for primer sequences). Cycling was 95 uC for 30 s, 58 uC for 30 s, 72 uC for 30 s with 30 cycles. PCR products were visualized by 1.8% agarose gel electrophoresis. ChIP-seq of H3K4me3. A human left hemisphere frontal cortex (Brodmann Area 10) was obtained from the Québec Suicide Brain Bank (QSBB, Montreal, Québec; http://www.douglasrecherche.qc.ca/brain-banks/suicide-bank.asp). All tissue was collected with written informed consent from next of kin. Experimentation with human brain tissue at the Genome Sciences Centre was carried out with approval from the University of British Columbia, British Columbia Cancer Agency Research Ethics Board (REB# H07-01589). For immunoprecipitation of H3K4me3-modified chromatin, human frontal cortex tissue (200-500 mg each) from a 57-year-old male suspended in chilled douncing buffer (250 ml; 10 mM Tris-HCl pH 7.5, 4 mM MgCl 2 , 1 mM CaCl 2 ), and homogenized by repeated pipetting followed by passing through a 1-ml 26-gauge syringe six times. The homogenate was then incubated with 5 U ml 21 of micrococcal nuclease (Sigma) for 7 min at 37 uC (,90% was mononucleosomes after digestion). The reaction was terminated by addition of EDTA (10 mM; ,5 ml). To this, 1 ml hypotonic lysis buffer (0.2 mM EDTA (pH 8.0), 0.1 mM benzamidine, 0.1 mM PMSF, 1.5 mM dithiothreitol) with protease inhibitor cocktail was added. The homogenate was incubated on ice for 60 min, with brief vortexing at 10 min intervals. The homogenate was centrifuged at 3,000g for 5 min, and the supernatant was transferred to a 1.5 ml non-stick tube. The micrococcal nuclease-digested chromatin fraction was pre-cleared with 100 ml of blocked Protein A/G Sepharose beads (Amersham) at 4 uC for 2 h, and following centrifugation the supernatant was transferred to fresh tubes. Chromatin immunoprecipitation was carried out either with anti-histone H3 trimethyl K4 (H3K4me3) antibody (ab8580, Abcam), or normal rabbit IgG antibody (12-370, Upstate Biotechnology) to assess fold enrichment. Antibodies were added in manufacturer-recommended amounts, and the mixtures incubated at 4 uC for 1 h. To each reaction mixture, 20 ml of Protein A/G beads were added and incubated by rotating at 4 uC overnight. Beads were recovered by centrifugation and washed twice with ChIP wash buffer (20 mM Tris-HCl pH 8.0, 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 150 mM NaCl) and once with ChIP final wash buffer (20 mM Tris-HCl pH 8.0, 0.1% SDS, 1% Triton X-100, 2 mM EDTA, 500 mM NaCl). DNA-antibody complexes were eluted using 100 ml elution buffer (100 mM NaHCO 3 , 1% SDS), and incubated with 5 mg of DNase-free RNase (Roche) at 68 uC for 2 h. The beads were pelleted by centrifugation and the supernatant was collected. Elution was repeated with addition of 100 ml of elution buffer and incubation at 68 uC for 5 min. After pooling the two eluates, DNA was recovered using the QIAquick PCR Purification kit (Qiagen). A ChIP-seq library was constructed as described previously using 11-35 ng of immunoprecipitated DNA. Categorization of CpG islands. We obtained genomic locations of CpG islands from the UCSC Genome Browser for human (hg18, 27,639 islands) and mouse (mm8, 15,948 islands) genome. We obtained RefSeq gene definition from the UCSC Genome Browser for human (hg18, 29,996 genes) and mouse (mm8, 22,307 genes) genome. We grouped CpG islands into four classes on the basis of their distance to RefSeq genes. They are (1) promoter islands (if an island ends after 1,000 bp upstream of a RefGene transcription start site, and starts before 300 bp downstream of a RefGene transcription start site); (2) intragenic islands (if an island starts after 300 bp downstream of a RefGene transcription start site and ends before 300 bp upstream of a RefGene transcription end site); (3) 39 transcript islands (if an island ends after 300 bp upstream of a RefGene transcription end site and starts before 300 bp downstream of a RefGene transcription end site); (4) intergenic islands (if an island starts after 300 bp downstream of a RefGene transcription end site and ends before 1,000 bp upstream of a RefGene transcription start site.
See Supplementary Fig. 12 for number of different classes of CpG islands in the human and mouse genomes. Definition of islands with no CpG. We identified 94,239 CpG-free regions in the human genome assembly (hg18) that span between 1 and 3 kb. We defined the middle 600 bp of these regions to be islands with no CpG. DNA methylation score for the mouse. We obtained reduced representation bisulphite sequencing data from ref. 16 . We included data on the following cell types in this analysis: primary astrocytes passage 2, B cell, brain, ES cell, liver, lung, spleen, T cell CD4 and T cell CD8. Methylation score for individual CpG site is defined as number of CG/(CG1TG) from bisulphite sequencing reads. A CpG site will have a defined methylation score only when CG1TG is equal to or greater than 5; otherwise, the score is undefined. Methylation score for individual CpG island is defined as the average score of all CpG sites with a defined methylation score within this island. The score is multiplied by 1,000.
A CpG island is defined as completely methylated if its methylation score is equal or greater than 500, as partially methylated if its methylation score is between 100 and 500, and as unmethylated if its methylation score is less than 100.
MeDIP-seq and methylation score for the human brain. We sequenced the same sample on Illumina GAI and GAII with a total number of approximately 106 million reads. Redundant reads were removed, and 47 million reads were mapped to the current human genome assembly (hg18) with MAQ. We extended each mapped reads to 200 bp in length. Overall, 24 million CpG sites are covered by at least one extended read. We define a methylation score for any region in the genome as number of extended reads per kb. A CpG island is defined as unmethylated if its methylation score is less than 20 reads kb 21 , as partially methylated if its methylation score is between 20 and 50 reads kb 21 , and as completely methylated if its methylation score is greater than 50 reads kb 21 . See Supplementary Fig. 3 for distribution of MeDIP-score across CpG sites and Supplementary Fig. 8 for MeDIP-score across CpG islands. MRE-seq and MRE-score for the human brain. We sequenced the same sample with Illumina GAI and GAII with a total number of approximately 20 million doi:10.1038/nature09165 reads. We mapped these reads to the human genome assembly (hg18) with MAQ with an additional constraint that the 59 end of a read must map to the CpG site within a MRE site. This resulted in about 11 million mapped MRE-reads. About 1.5 million CpG sites have at least one mapped MRE-read. We define MRE-score for each CpG site as the number of MRE-reads that map to the site, regardless of the orientation. We define MRE-score for each CpG island as the average MREscore for all CpG sites that have a score within the island. See Supplementary  Fig. 2 for a distribution of MRE-score across CpG sites and Supplementary Fig. 7 for MRE-score across CpG islands. NIC (normalized internal coverage) score. For any genome-wide data presented in wiggle format, NIC for any given region is defined as the total area of the data profile within the region normalized by the length of the region. See Supplementary Fig. 13 for distribution of NIC scores of CpG islands with respect to H3K4me3. CAGE association. We used published mouse and human CAGE data. Tissuespecific CAGE data are available as wiggle tracks. For each CpG island, we extend the island boundary by 200 bp in both upstream and downstream directions. If the extended island overlaps with any wiggle signal from the CAGE data set, we calculate NIC score for the island. Identifying conserved CpG islands between human and mouse. We first syntenically mapped all human CpG islands to the mouse genome assembly (mm8) and filtered out those that do not map. We further filtered out those that, when mapped to the mouse, do not overlap annotated CpG islands. Next, we compared classification of these islands (promoter, intragenic, 39 of transcript or intergenic) and filtered out those pairs whose classifications do not match. This results in 2,400 pairs of conserved CpG islands between human and mouse, 500 of which are intragenic. RNA-seq, identification of putative transcription start sites, gene expression measurements. Total RNA (100 ng) was used to synthesize full-length singlestranded cDNAs using the SMART PCR cDNA Synthesis Kit (Clontech) following the protocol described in ref. 30 . The resulting double-stranded cDNAs were assessed using an Agilent DNA 1000 series II assay (Agilent) and Nanodrop 7500 spectrophotometer (Nanodrop). Sonication was performed for a total of 50 min using Bioruptor UCD-200 (Diagenode). The sheared cDNA was size-separated by 8% PAGE and the 200-250 bp DNA fraction excised and eluted from the gel slice overnight at 4 uC in 300 ml elution buffer (5:1, LoTE buffer (3 mM Tris-HCl, pH 7.5, 0.2 mM EDTA) with 7.5 M ammonium acetate), and purified using a QIAquick purification kit (Qiagen). The library was constructed following the Illumina genomic DNA paired-end library protocol with 10 cycles of PCR (Illumina). The resulting PCR product was purified using 8% PAGE to remove small products including adaptor dimers, and the DNA quality was assessed using an Agilent DNA 1000 series II assay and quantified with a Qubit fluorometer (Invitrogen) and then diluted to 10 nM. The final concentration was doublechecked and determined by Quant-iT dsDNA HS Assay Kit with a Qubit fluorometer (Invitrogen). Cluster generation and paired-end sequencing was performed on the Illumina cluster station and Genome Analyzer following manufacturer's instructions (Illumina).
In total, 93 million paired-end reads (186 million reads) were generated for the frontal cortex WTSS-lite library. Custom scripts were used to identify 56.4 million reads that contained the SMART oligo sequence and a variable G stretch (added by the RT terminal transferase activity) on the 59 end. Putative TSS were found by identifying WTSS reads containing sequence corresponding to SMART oligo tags, clipping these tags informatically, and aligning the resulting sequence tag (representing the 59 end of a full-length mRNA) using MAQ. In detail, paired end reads were split into forward (read1) and reverse (read2) reads. Read1s were parsed for those that contained reads starting with the SMART tag followed by a variable number of Gs and clipped after the terminal G. These variable-length sequence strings were written to the SMART file (56.4 million reads). All read2s and those read1s that did not contain the SMART sequence tag were written to a NOSMART file (129.6 million reads). The SMART file was split into 14 subfiles on the basis of read length and MAQ (0.7.1) alignments were run and the resulting .map files merged. The NOSMART file was split into two subfiles (for the 75 and 50 bp read lengths), and MAQ aligned and the resulting .map files merged. The .map files were used to generate SMART and NOSMART wig tracks using FindPeaks 2 (xset5; no threshold). For gene expression analysis, the clipped and non-clipped reads were pooled (SMART and NOSMART .map files merged), and read counts generated at the exon and gene level using custom scripts.
To assess promoter activities of individual CpG islands, we first extended each island boundary by 200 bp in both upstream and downstream directions and looked for evidence of TSS based on RNA-seq data in these regions. We tallied number of SMART and NOSMART RNA-seq reads overlapping with each island, and defined TSS activity as (1) having at least five SMART-tagged reads, and (2) at least 70% of total RNA-seq reads are SMART tagged reads.
